9.63  -1.37 (-12.45%)		12-31 19:00
Open: 11 High: 11.0973 Volume: 988,303		Pre. Close: 11 Low: 9.59 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	13.47	1-year :	15.74
Resists	First :	11.54	Second :	13.47
Pivot price	10.78
Supports	First :	9.69	Second :	8.55
MAs	MA(5) :	10.76	MA(20) :	10.83
	MA(100) :	10.87	MA(250) :	10.64
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	80.9	D(3) :	77.7
RSI	RSI(14): 54.5
52-week	High :	11.59	Low :	8.55

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ NETC ] has closed below upper band by 34.2%. Bollinger Bands are 381.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	11.55 - 11.6	11.6 - 11.64
Low:	10.78 - 10.83	10.83 - 10.88
Close:	10.91 - 10.99	10.99 - 11.07

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.

Fri, 30 Jul 2021
AMZN Stock Price Predictions: What Will Amazon Be Worth in 2025? 2030? - InvestorPlace

Mon, 26 Jul 2021
Do Analysts Expect Intec Pharma Ltd (NTEC) Stock to Rise After It Is Lower By -25.07% in a Month? - InvestorsObserver

Wed, 09 Dec 2020
Intec Pharma News: Why NTEC Stock Is on Fire Today - InvestorPlace

Mon, 12 Oct 2020
Marijuana Stocks July 2019 - Stocks Newswire

Fri, 09 Oct 2020
Sen. Harris Commits to Decriminalizing Weed and Other Sector News - Schaeffers Research

Wed, 07 Oct 2020
Best Medical Marijuana Stocks (NYSE: IIPR), (OTCMKTS: MRMD), (OTCMKTS: MMNFF), (OTCMKTS: ALEAF ... - Stocks Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	10 (M)
Shares Float	8 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	7 (K)
Shares Short P.Month	1 (K)

EPS	-0.02
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.63
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-2.3 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	11.3 %
Operating Cash Flow	-3 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-550
PEG Ratio	0
Price to Book value	-17.47
Price to Sales	0
Price to Cash Flow	-36

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.